Wolfgang Ekkehard Schmidt

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Michael Albrecht Nauck · 1 shared paper, 2017 · strength 0.12
   • Paper Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring dat… DOI 10.1111/dom.12981↗
2. Ralf‐Dieter Hofheinz · 2 shared papers, 2013–2017 · strength 0.08
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
   • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
3. Beate S. Schultheis · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
4. Markus Dommach · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
5. Sara De Dosso · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
6. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
7. Dirk Strumberg · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
8. Şuayib Yalçın · 1 shared paper, 2017 · strength 0.05
   • Paper Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients… DOI 10.1093/annonc/mdx343↗
9. Heiko Fensterer · 1 shared paper, 2013 · strength 0.03
   • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
10. Utz Settmacher · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
11. Detlef Klaus Bartsch · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
12. Patrick Michl · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
13. Thomas Mathias Gress · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
14. Marko Kornmann · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
15. Esther Endlicher · 1 shared paper, 2013 · strength 0.03
    • Paper Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therap… DOI 10.1093/annonc/mdt270↗
16. Gyorgy Bodoky · 1 shared paper, 2012 · strength 0.03
    • Paper Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a rand… DOI 10.1093/annonc/mdr379↗
17. Manfred Paul Lutz · 1 shared paper, 2012 · strength 0.03
    • Paper Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a rand… DOI 10.1093/annonc/mdr379↗
18. Matthias J. Löhr · 1 shared paper, 2012 · strength 0.03
    • Paper Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a rand… DOI 10.1093/annonc/mdr379↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.